Methods of detecting myelin basic protein

A method of imaging nerves in a surgical field, comprising:

• contacting a surgical site of a subject with an agent which binds to myelin basic protein (MBP) and wherein said agent comprises;
• a compound of Formula I, a 13C enriched compound of Formula I, a 19F-labeled derivative of Formula I, or a radioisotope derivative of Formula I or combinations thereof;
• wherein R1 and R2 are independently at each occurrence a hydrogen, hydroxyl group, C1-C30 aliphatic radicals, C3-C30 cycloaliphatic radicals, or C2-C30 aromatic radicals with the proviso that R1 and R2 are not both equal to a hydroxyl group;
• R3 is hydrogen, a hydroxyl group, an alkoxy group, a C1-C6 hydroxyalkyl group, a C1-C6 alkyl group or a substituted alkyl group;
• and
• the summation of alkyl groups of R1, R2 and R3 is less than or equal to 16 carbon atoms;
• and
• detecting the agent.

A method of quantifying an amount of myelin basic protein (MBP) present in a tissue sample, comprising:

• contacting the tissue sample with an agent wherein said agent comprises;
• a compound of Formula I, a 13C enriched compound of Formula I, a 19F-labeled derivative of Formula I, or a radioisotope derivative of Formula I or combinations thereof;
• wherein R1 and R2 are independently at each occurrence a hydrogen, a hydroxyl group, C1-C30 aliphatic radicals, C3-C30 cycloaliphatic radicals, or C2-C30 aromatic radicals with the proviso that R1 and R2 are not both equal to a hydroxyl group;
• R3 is hydrogen, a hydroxyl group, an alkoxy group, a C1-C6 hydroxyalkyl group, a C1-C6 alkyl group or a substituted alkyl group;
• and
• the summation of alkyl groups of R1, R2 and R3 is less than or equal to 16 carbon atoms;
• detecting the agent present in the tissue sample;
• and
• quantifying an amount of the agent present in the tissue sample.

A kit for detecting myelin-associated neuropathy in a subject, comprising:

• an agent wherein said agent binds to myelin basic protein (MBP) and comprises;
• a compound of Formula I, a 13C enriched compound of Formula I, a 19F-labeled derivative of Formula I, or a radioisotope derivative of Formula I or combinations thereof;
• wherein R1 and R2 are independently at each occurrence a hydrogen, hydroxyl group, C1-C30 aliphatic radicals, C3-C30 cycloaliphatic radicals, or C2-C30 aromatic radicals with the proviso that R1 and R2 are not both equal to a hydroxyl group;
• R3 is hydrogen, a hydroxyl group, an alkoxy group, a C1-C6 hydroxyalkyl group, a C1-C6 alkyl group or a substituted alkyl group;
• and
• the summation of alkyl groups of R1, R2 and R3 is less than or equal to 16 carbon atoms;
• and
• a pharmaceutically acceptable carrier.